Literature DB >> 23239500

Bruton's tyrosine kinase mediates FcγRIIa/Toll-like receptor-4 receptor crosstalk in human neutrophils.

Agnieszka Krupa1, Rafal Fudala, Jon M Florence, Torry Tucker, Timothy C Allen, Theodore J Standiford, Rafal Luchowski, Marek Fol, Moshiur Rahman, Zygmunt Gryczynski, Ignacy Gryczynski, Anna K Kurdowska.   

Abstract

Previous observations by our laboratory indicate that the presence of anti-IL-8 autoantibody:IL-8 immune complexes in lung fluids from patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) comprises an important prognostic indicator in the development and ultimate outcome of ALI/ARDS. We also showed that these complexes display proinflammatory activity toward neutrophils through the engagement of FcγRIIa receptors. Because sepsis is one of the most common risk factors for ALI/ARDS, the initial goal of our present study involved investigating the effects of LPS on the expression of FcγRIIa receptors in neutrophils. Our results indicate that LPS triggers an increase in the expression of FcγRIIa on the neutrophil surface, which leads to shortening of the molecular distance between FcγRIIa and Toll-like receptor-4 (TLR4). When such neutrophils are stimulated with anti-IL-8:IL-8 complexes, the TLR4 cascade becomes activated via the engagement of FcγRIIa. The underlying molecular mechanism has been subsequently examined and involves Bruton's tyrosine kinase (Btk). In conclusion, our study reveals the existence of Btk-dependent molecular cooperation between FcγRIIa and TLR4 signaling cascades in LPS-"primed" human neutrophils. Furthermore, we used fluorescence lifetime imaging to study the interactions between TLR4 and FcγRIIa in human alveolar neutrophils from patients with ALI/ARDS. The results from these experiments confirm the existence of the molecular cooperation between TLR4 and FcγRIIa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239500      PMCID: PMC3604059          DOI: 10.1165/rcmb.2012-0039OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  53 in total

Review 1.  Tec kinases: a family with multiple roles in immunity.

Authors:  W C Yang; Y Collette; J A Nunès; D Olive
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

2.  Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.

Authors:  S Nisitani; A B Satterthwaite; K Akashi; I L Weissman; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  The role of CD47 in neutrophil transmigration. Increased rate of migration correlates with increased cell surface expression of CD47.

Authors:  Y Liu; D Merlin; S L Burst; M Pochet; J L Madara; C A Parkos
Journal:  J Biol Chem       Date:  2001-07-30       Impact factor: 5.157

4.  Bruton's tyrosine kinase associates with the actin-based cytoskeleton in activated platelets.

Authors:  S Mukhopadhyay; A S Ramars; D Dash
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

5.  The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils.

Authors:  Fumiko Honda; Hirotsugu Kano; Hirokazu Kanegane; Shigeaki Nonoyama; Eun-Sung Kim; Sang-Kyou Lee; Masatoshi Takagi; Shuki Mizutani; Tomohiro Morio
Journal:  Nat Immunol       Date:  2012-02-26       Impact factor: 25.606

6.  Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts.

Authors:  A Pfeiffer; A Böttcher; E Orsó; M Kapinsky; P Nagy; A Bodnár; I Spreitzer; G Liebisch; W Drobnik; K Gempel; M Horn; S Holmer; T Hartung; G Multhoff; G Schütz; H Schindler; A J Ulmer; H Heine; F Stelter; C Schütt; G Rothe; J Szöllôsi; S Damjanovich; G Schmitz
Journal:  Eur J Immunol       Date:  2001-11       Impact factor: 5.532

Review 7.  Tec family kinases in lymphocyte signaling and function.

Authors:  E M Schaeffer; P L Schwartzberg
Journal:  Curr Opin Immunol       Date:  2000-06       Impact factor: 7.486

8.  Anti-interleukin 8 autoantibody: interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity.

Authors:  A Kurdowska; J M Noble; K P Steinberg; J T Ruzinski; L D Hudson; T R Martin
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

9.  Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B.

Authors:  Q Jiang; S Akashi; K Miyake; H R Petty
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

10.  Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome.

Authors:  Anna Kurdowska; James M Noble; Ian S Grant; Colin R Robertson; Christopher Haslett; Seamas C Donnelly
Journal:  Crit Care Med       Date:  2002-10       Impact factor: 7.598

View more
  15 in total

1.  Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.

Authors:  Jon M Florence; Agnieszka Krupa; Laela M Booshehri; Sandra A Davis; Michael A Matthay; Anna K Kurdowska
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-08       Impact factor: 5.464

Review 2.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

3.  Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.

Authors:  Agnieszka Krupa; Marek Fol; Moshiur Rahman; Karen Y Stokes; Jon M Florence; Igor L Leskov; Mikhail V Khoretonenko; Michael A Matthay; Kathleen D Liu; Carolyn S Calfee; Amy Tvinnereim; Gabriel R Rosenfield; Anna K Kurdowska
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-08-01       Impact factor: 5.464

4.  Fcγ receptors and toll-like receptor 9 synergize to drive immune complex-induced dendritic cell maturation.

Authors:  Nicole L J Nelson; Cheryl M Zajd; Michelle R Lennartz; Edmund J Gosselin
Journal:  Cell Immunol       Date:  2019-08-03       Impact factor: 4.868

5.  Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus.

Authors:  Stanley Moore; Hsin-Hsuan Juo; Christoffer T Nielsen; Helena Tyden; Anders A Bengtsson; Christian Lood
Journal:  J Rheumatol       Date:  2019-12-15       Impact factor: 4.666

Review 6.  Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling.

Authors:  Agnieszka Płóciennikowska; Aneta Hromada-Judycka; Kinga Borzęcka; Katarzyna Kwiatkowska
Journal:  Cell Mol Life Sci       Date:  2014-10-22       Impact factor: 9.261

7.  Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants.

Authors:  Sun Ku Lee; Jun Xing; Ian M Catlett; Robert Adamczyk; Amber Griffies; Ang Liu; Bindu Murthy; Miroslawa Nowak
Journal:  Eur J Clin Pharmacol       Date:  2017-03-06       Impact factor: 2.953

8.  Metalloproteinase-9 contributes to endothelial dysfunction in atherosclerosis via protease activated receptor-1.

Authors:  Jon M Florence; Agnieszka Krupa; Laela M Booshehri; Timothy C Allen; Anna K Kurdowska
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

9.  A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.

Authors:  Ehsanollah Esfandiari; Mary Chen; Glennda Smithson; Derek Blair; Helene Faessel; John Wagner; Lachy Mclean; Eric R Fedyk
Journal:  Clin Transl Sci       Date:  2021-03-02       Impact factor: 4.689

10.  Granulocyte-augmented chemokine production induced by type II collagen containing immune complexes is mediated via TLR4 in rheumatoid arthritis patients.

Authors:  Vivek Anand Manivel; Azita Sohrabian; Johan Rönnelid
Journal:  Eur J Immunol       Date:  2016-10-05       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.